| Document |
Document Title |
|
WO/2024/015678A1 |
Disclosed are methods of treating cancer in a subject comprising (i) administering a pharmaceutical composition comprising a therapeutically effective amount of a mutagenized IL13 moiety (mIL13); and then (ii) delivering a radiation ther...
|
|
WO/2024/015881A2 |
Provided in some aspects are transcriptional activation domains for targeted transcriptional activation. Also provided are multipartite effectors, fusion proteins, and DNA-targeting systems, such as CRISPR/Cas-based DNA-targeting systems...
|
|
WO/2024/013402A1 |
Novel soluble γT-cell receptor chains, soluble δT-cell receptor chains, soluble γδTCRs, or fragments thereof, mediating anti-tumour responses or anti-infective responses are provided.
|
|
WO/2024/015723A1 |
Engineered tunable chimeric receptor/ligand pairs, and methods of use thereof, are provided.
|
|
WO/2024/013381A1 |
The invention relates to a method of detecting an interaction or proximity between a fusion protein and a target protein. The method may comprise a) providing a fusion protein and/or a recombinant nucleic acid molecule encoding said fusi...
|
|
WO/2024/015877A2 |
Disclosed herein are recombinant AAV variant (e.g., variant serotype 3B (AAV3B)) capsid proteins and variant capsid protein-containing viral particles with enhanced ability to transduce hepatic cells. Viral particles containing these cap...
|
|
WO/2024/013727A1 |
Antigen-binding molecules that are engineered to replace the light chain constant domain (CL) and heavy chain constant domain 1 (CH1) with HLA class I histocompatibility antigen alpha chain-E alpha-3 (HLA-E)/Beta-2 microglobulin (B2M) or...
|
|
WO/2024/011946A1 |
Provided is a polypeptide dimer for the treatment of systemic sclerosis.
|
|
WO/2024/014989A1 |
The inventions relate to a recombinant protein GBD-ActRIIB containing an ActRIIB receptor fragment and a glucan-binding domain GBD, a method for producing said recombinant protein, a preparation for increasing muscle mass in livestock an...
|
|
WO/2024/014972A2 |
The subject of the invention is a recombinant hybrid protein RElSmR composed sequentially of 3 resilin domains, 1 K+ domain, 1 MMP domain, 3 elastin domains, 1 K+ domain, 4 elastin domains, 1 K+ domain, 4 elastin domains, 1 K+ domain, 3 ...
|
|
WO/2024/012457A1 |
The present invention relates to a trispecific antibody specifically binding to CD19, CD3, and CD28, which trispecific antibody contains a fragment derived from an IgD hinge region as a linker. The present invention also relates to the u...
|
|
WO/2024/013742A1 |
Cells comprising a heterologous nucleic acid sequence that encodes for a trehalase enzyme and optionally a heterologous nucleic acid sequence that encodes for a trehalose transporter protein are provided. Pharmaceutical compositions comp...
|
|
WO/2024/015743A1 |
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen VCY CT...
|
|
WO/2024/012278A1 |
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and an antigen encoded by an exogenous gene. Compared with the amino acid sequence represented by SEQ ID NO 1, the M p...
|
|
WO/2024/015982A2 |
Disclosed herein are modified HIV envelope immunogens, engineered nanoparticle vaccines comprising modified HIV envelope immunogens and methods of use thereof for HIV vaccines.
|
|
WO/2023/156663A9 |
Specific binding molecules, including T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17 are presented. TCRs of the present invention comprise non-natur...
|
|
WO/2024/012912A1 |
The present invention relates to polypeptides having deamidase inhibitor activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotide...
|
|
WO/2024/012277A1 |
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and a cytokine encoded by an exogenous gene. Compared with the amino acid sequence as shown in SEQ ID NO. 1, the M pro...
|
|
WO/2024/012540A1 |
Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, egg secreted proteins, etc. (hereinafter referred to as "Schistosoma eggs and secretions and exc...
|
|
WO/2024/013770A1 |
The present invention relates to substituted 3-methylbenzo[d]thiazol-3-ium compounds, their nucleic acid conjugates, complexes, salts which are potentially useful for cell imaging applications, diagnostics, fluorescent tags, pharmaceutic...
|
|
WO/2024/015925A2 |
This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR/Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The d...
|
|
WO/2024/013350A1 |
The invention relates to a bacteriophage targeting capsular-deficient Klebsiella pneumoniaee (Kp), comprising particular tail fiber polypeptides, which is capable of infecting at least two capsular- deficient Klebsiella pneumoniae of dis...
|
|
WO/2024/013749A1 |
Provided herein are plant cells genetically modified to express at least one milk protein naturally expressed by a mammal a mammal and at least one protein promoting at least one post translation modification in said at least one milk pr...
|
|
WO/2024/012472A1 |
A long-acting GLP-1/GIP dual agonist compound, wherein the compound has dual agonistic effects on a glucagon-like peptide-1 (GLP-1) receptor and a human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention a...
|
|
WO/2024/008126A1 |
Provided are IL2 muteins (or "IL2 mutants"), an isolated polynucleotide encoding the IL2 mutein, an isolated vector containing the polynucleotide, a host cell containing the isolated polynucleotide or the isolated vector which encoding t...
|
|
WO/2024/011237A1 |
The present disclosure provides methods and compositions for the treatment of Alzheimer's disease. The methods and compositions of the present disclosure comprise AAV vectors and AAV viral vectors comprising transgene nucleic acid molecu...
|
|
WO/2024/011104A1 |
The present application relates to functionally improved third generation BCMA-CARs comprising modified intracellular co-stimulatory domains, which can be used in adoptive cell therapy, e.g., in treatment of diseases and disorders such a...
|
|
WO/2024/010957A2 |
Provided herein are peptides and conjugates, including radionuclide conjugates, useful in compositions and methods of treating, diagnosing, monitoring, and/or imaging a disease, disorder, or condition associated with expression of one or...
|
|
WO/2024/011143A2 |
Embodiments are directed to a UPEC conjugate peptide including a self- assembling peptide and at least one UPEC epitope. The UPEC conjugate peptide may self- assemble into a nanofiber or fibril. Compositions including the UPEC conjugate ...
|
|
WO/2024/011188A1 |
The disclosure provides methods for the treatment and/or prevention of iron overload diseases such as hereditary hemochromatosis.
|
|
WO/2024/010783A1 |
The present disclosure provides enzymes derived from the fungi Fusarium oxysporum c8D ("FoPip4H enzymes") having improved properties as compared to a naturally occurring wild-type enzyme including the capability of hydroxylating certain ...
|
|
WO/2024/007362A1 |
The present invention relates to use of a homoharringtonine compound in the preparation of a medicament for treating AIDS. The beneficial effects are: the homoharringtonine obtained by screening can effectively reduce the occurrence of H...
|
|
WO/2024/011159A1 |
Described herein is a method for increasing expression of the MHY6 gene in a cell by genome editing comprising introducing into the cell one or more DNA endonucleases within or near enhancer regions of the MYH6 gene that results in activ...
|
|
WO/2024/010785A1 |
The present disclosure provides ketoreductase enzymes having improved enzymatic properties including the capability of reducing hydroxy indanones to provide diastereomerically pure 1,3-indane diols useful for the synthesis of belzutifan....
|
|
WO/2024/010085A1 |
Provided is a mutant OCT3/4 protein that is capable of inducing reprogramming of somatic cells at higher efficiency than an OCT3/4 protein composed of a natural amino acid sequence. Also provided is a method for efficiently producing iPS...
|
|
WO/2024/010489A2 |
The invention relates to genetic and protein engineering and can be used in medicine and the pharmaceutical industry. Recombinant plasmid DNA pET23b-CBD-HS-ES-GLP1, pET-parB-CBD-HS-ES-GLP1 and pET23bKanR-CBD-HS-ES-GLP1 were constructed t...
|
|
WO/2024/008274A1 |
The invention relates to methods for modifying T regulatory cells by introducing RNApolynucleotides thereto by electroporation, and further pertains to the modified Treg cells and their compositions and uses.
|
|
WO/2024/011229A1 |
Provided are compositions and method for prophylaxis and/or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The co...
|
|
WO/2024/009146A2 |
The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. The invention also provides transgenic plants, plant cells, plant p...
|
|
WO/2024/011211A2 |
The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: an orthopoxvirus or an immune response relevant to an orthopoxvirus infection including T cells responsive to one or mor...
|
|
WO/2024/011179A1 |
The disclosure provides methods of treating a blood cancer, such as multiple myeloma, by administering a combination of a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer c...
|
|
WO/2024/011265A2 |
Provided are proteins and peptides including the sequence -RXKF-, where X is a 2-thiohistidine residue or 2-thiohistidine residue analogue and each residue of the sequence has D or L stereochemistry. Also provided are compositions and me...
|
|
WO/2024/007872A1 |
Disclosed are a CD80 IgV mutant polypeptide, a CD80 mutant fusion polypeptide complex comprising the mutant polypeptide, and a nucleotide molecule functioning as a fusion protein and expressing the mutant fusion polypeptide complex. Furt...
|
|
WO/2024/010118A1 |
A novel antibody, which specifically binds to BDCA-2, according to the present invention recognizes BDCA-2 at a similar level to known antibodies, and mediates the internalization of BDCA-2 from the surface of plasmacytoid dendritic cell...
|
|
WO/2024/010557A1 |
The present invention relates to a method (100) for extracellular secretion of recombinant proteins (G) secreted by gram-negative bacteria, without the need for additional protein secretion systems.
|
|
WO/2024/007358A1 |
Provided are an antibody binding to human CD207, an anti-human CD207 chimeric antigen receptor, and use thereof, relating to the technical field of biological medicines. The antibody has high affinity for a CD207 protein and can be used ...
|
|
WO/2024/011163A1 |
The present disclosure relates to coronavirus vaccines and methods for use thereof.
|
|
WO/2024/008966A1 |
An epigenetic silencer factor (ESP), or polynucleotide encoding therefor, for use in the treatment of cancer, wherein the ESF comprises a transcription factor DNA-binding domain operably linked to at least one epigenetic effector domain,...
|
|
WO/2024/008014A1 |
Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-...
|
|
WO/2024/008205A1 |
The present invention belongs to the technical fields of genetic engineering and enzyme engineering, and specifically relates to the use of MmBBK2 in the preparation of trypsin and chymotrypsin inhibitors. The MmBBK2 has an amino acid se...
|
